Gossamer Bio, Inc. Common Stock (GOSS)
Gossamer Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies primarily for rare, serious, and underserved diseases. The company's pipeline includes innovative treatments in areas such as immunology, inflammation, and oncology, aiming to address unmet medical needs through novel scientific approaches.
Company News
Respira Therapeutics has granted Gossamer Bio an option to acquire the company, focusing on developing RT234, an investigational as-needed treatment for pulmonary hypertension. The agreement includes stock issuance and potential milestone payments.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.
This article highlights upcoming events in the financial world, including quarterly earnings reports, IPOs, investor events, and market volatility updates.
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Penny stocks to buy according to these insiders in November 2023. The post 5 Penny Stocks To Buy Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.